Neurotoxicity of the CNS: diagnosis, treatment and prevention

Rev Neurol (Paris). 2011 Oct;167(10):737-45. doi: 10.1016/j.neurol.2011.08.005. Epub 2011 Sep 6.

Abstract

Treatment-induced CNS toxicity remains a major cause of morbidity in patients with cancer. Real advances in the design of safer radiation procedures have been counterbalanced by a wider use of combined radiotherapy (RT)-chemotherapy regimens, the development of radiosurgery, and the increasing number of long-term survivors. While classic radionecrosis or chemonecrosis have become less common, more subtle changes such as progressive cognitive dysfunction are increasingly reported after RT (radiation-induced leukoencephalopathy) or chemotherapy (administered alone or in combination). The most important and controversial complications of RT, chemotherapy and combined treatments in the CNS are reviewed here, including new diagnostic tools, practical management and prevention that will influence the future management of cancer patients.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / complications
  • Brain Neoplasms / radiotherapy
  • Cognition Disorders / etiology
  • Combined Modality Therapy / adverse effects
  • Humans
  • Leukoencephalopathies / chemically induced
  • Leukoencephalopathies / etiology
  • Magnetic Resonance Imaging
  • Neoplasms / complications*
  • Neoplasms / drug therapy
  • Neoplasms / radiotherapy
  • Neurotoxicity Syndromes / etiology*
  • Neurotoxicity Syndromes / pathology
  • Neurotoxicity Syndromes / prevention & control
  • Neurotoxicity Syndromes / therapy*
  • Radiotherapy / adverse effects*

Substances

  • Antineoplastic Agents